Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12451 - 12475 of 15129 in total
Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).
Investigational
Matched Description: … under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and
MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).
Investigational
Matched Description: … MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics …
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
Investigational
Matched Description: … under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and
IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients).
Investigational
Matched Description: … IONIS-FGFR4Rx is under investigation in clinical trial NCT02476019 (A Safety, Tolerability, PK, and PD …
Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Investigational
Matched Description: … Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy …
Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]
Investigational
Matched Description: … probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability ... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and
Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also...
Investigational
Matched Description: … This is followed by purification and expansion of the cells in vitro. ... Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and ... multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and
SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.
Investigational
Matched Description: … the most promising compound from a new series of renin inhibitors for the treatment of hypertension and
Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.
Investigational
Matched Description: … P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and
XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.
Investigational
Matched Description: … monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and
ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
Investigational
Matched Description: … ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell …
Emixustat has been used in trials studying the treatment of Geographic Atrophy, Age-Related Macular Degeneration, and Dry Age-related Macular Degeneration.
Investigational
Matched Description: … been used in trials studying the treatment of Geographic Atrophy, Age-Related Macular Degeneration, and
PAC-1 has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.
Investigational
Matched Description: … has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and
Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Experimental
Matched Description: … It is an antagonist at D1 and D2 dopamine receptors. …
Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Investigational
Matched Description: … Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and
ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
Investigational
Matched Description: … ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And
Seviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).
Investigational
Matched Description: … is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and
Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Investigational
Matched Description: … Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung …
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and
Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.
Investigational
Matched Categories: … Calcium-Regulating Hormones and Agents …
AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and...
Investigational
Matched Description: … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma …
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical. The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements.
Investigational
Displaying drugs 12451 - 12475 of 15129 in total